The biotechnology start-up Ambagon Therapeutics has raised 75 million euros (85 million dollars) in a financing round. With the money, the Dutch-American company will develop medicines that can be used to better treat cancer in the future. Ambagon was founded in 2020 on the basis of a number of years of research at TU Eindhoven by Eline Sijbesma, Loes Stevers and others.
Biotech startup Ambagon Therapeutics is taking a new approach to making elusive protein targets “druggable” by using molecular glues. The biotech has a pipeline of preclinical cancer drugs and it has raised $85 million to support their development.
Modular platform enables development of molecular glue stabilizers addressing intrinsically disordered proteins, a largely undrugged target classInitial discovery pipeline focused on high-value targets in oncologySAN FRANCISCO (BUSINESS WIRE) Ambagon Therapeutics, a biotechnology company unlocking intrinsically di.